

Epidemiology and burden of viral hepatitis in Krasnodar Region.




Bahtina V.A.


Moscow, 25-26 October 2018

Morbidity of chronic viral hepatitis (KK and RF for the population of 100,000)


MORBIDITY OF THE NEWLY-DIAGNOSED CHRONICAL VIRAL HEPATITIS, MORBIDITY RATE OF NEWLY DIAGNOSED CHRONIC VIRAL HEPATITIS, FOR THE POPULATION OF 100,000



INCL. VHB, FOR THE POPULATION OF 100,000




INCL. VHC, FOR THE POPULATION OF 100,000




Basic scenario of the course of the epidemiological process


Patients treated




Patients with achieved SVR



Total number of the infected persons



New cases of the infection contamination




**Growth of the total number of the infected pers.,
from 177 980 in 2017 to 208 400 in 2030**

**Annual intrinsic growth of new patients with CHC will average
out at 10 470 people**


Basic scenario of the course of the epidemiological process

Total mortality rate




**Total mortality rate growth from 5 018 in 2017
to 5959 in 2030**

Mortality rate due to liver injury




**Growth of the mortality rate due to liver injury,
from 250 in 2017 to 421 in 2030**

**Cases of decompensated liver cirrhosis as the outcome of
CHC**




**Growth of patients with decompensated liver
cirrhosis from 682 in 2017 to 1 127 in 2030**

**Cases of hepatocellular carcinoma development among CHC
patients**




**Growth in the number of hepatocellular carcinoma
development cases from 223 in 2017 to 391 in 2030**


Surveillance system «Viral hepatitis patients registry»



Total number




Age groups



Surveillance system «Viral hepatitis patients registry»




Chronic viral hepatitis



■ ХГВ (3438: 16%) ■ ХГВ+D (474: 2%) ■ НВГВ (109: <1%) ■ ХГС (16646: 79%)
■ ХВГ сочетанной этиологии (268: 1%)

HVC genotypes




■ 1 (2189: 38%) ■ 1a (29: <1%) ■ 1b (792: 13%) ■ 2k/1b (2: <1%) ■ 2 (585: 10%)
■ 3 (2104: 36%)


Surveillance system «Viral hepatitis patients registry»



Fibrosis stages



Outcomes



Specialized clinical hospital for infectious diseases

Hepatology center structure




TREATMENT AND DIAGNOSTIC UNIT

- FOLLOW-UP CARE OFFICE
- OUT-PATIENT OFFICE
- DIAGNOSTIC OFFICES (EGD, U/S, FIBROSCAN)
- DAY-PATIENT FACILITY
- 24/7 HEPATOLOGY UNIT
- IMMUNOPROPHYLAXIS OFFICE

CLINICAL-DIAGNOSTIC LABORATORY

MICROBIOLOGICAL LABORATORY



LIVER TRANSPLANT


SBHI «RESEARCH AND DEVELOPMENT INSTITUTION – KRAI CLINICAL HOSPITAL №1, NAMED AFTER PROF. OCHAPOVSKIY»

SBHI «KRAI CLINICAL HOSPITAL №2»

Hepatitis school




Linkage to care



**MEDICAL ORGANISATIONS
OF MUNICIPAL ENTITY**

- CASE DETECTION
- INITIAL EXAMINATION
- REGISTRATION OF THE PATIENT



**HOSPITALS FOR INFECTIOUS DISEASES
(ARMAVIR, NOVOROSIISK,
KRASNODAR, SOCHI)**

- IN-PATIENT EXAMINATION
- SPECIFICATION OF THE ACTIVITY
PHASE



СКИБ

HEPATOLOGY CENTRE

- **KRAI MEDICAL PANEL**
- **KRAI PATIENTS REGISTRY**
- **SPECIALIZED CARE:**
OUT-PATIENT
HOSPITAL-SUBSTITUTING
HOSPITAL

Funding sources



PERSONS, ENTITLED TO SOCIAL BENEFITS:

- FEDERAL BUDGET
- LOCAL BUDGET



FORMS OF COMPULSORY MEDICAL INSURANCE

DIAGNOSIS-RELATED GROUPS, PROVIDING ANTIVIRAL MEDICATION IN DAY-PATIENT TREATMENT SETTING




PERSONAL SAVINGS




THERE IS NO SPECIAL TARGET PROGRAMME

Percentage of sources, providing antiviral medication


Funding sources in 2016-2017



Covered by social benefits, pers.



Covered by personal savings, pers.




**Compulsory
Medical
Insurance**




**2016
104 pers.**

**2017
110 pers.**

The cost of the 4-week treatment (clinical statistical group # 26)



The cost of the 4-week treatment (clinical statistical groups # 23 -24)



MAX
cost of clinical
statistical group # 24
119 516,76 (CP 2,3),
without CP 20 450,65

Estimated changes in the CHC epidemiologic situation : WHO strategy scenario

- Gradual increase in the numbers of treated patients, up to 5 060 persons per year;
- Gradual increase in the numbers of newly-diagnosed patients, up to 14 140 persons per year;
- Gradual decrease of morbidity rate, so far as 1 030 cases per year;
- Treatment of advanced fibrosis $\geq$ F3.

	2017	2018	2019	2020	2022	2030
Newly-diagnosed patients	1 680	2 510	3 770	9 430	14 140	14 140
Patients treated	740	1 110	1 670	2 500	3 380	5 060
Cases of infection contamination	10 390	10 400	7 290	4 370	2 160	1 030
Fibrosis stages	$\geq$ F1	$\geq$ F3	$\geq$ F3	$\geq$ F3	$\geq$ F2	$\geq$ F2
Age of in-treatment patients	15-74	15-74	15-74	15-74	15-74	15-74
SVR	90%	90%	90%	95%	95%	95%


Estimated changes in the CHC epidemiologic situation : WHO strategy scenario

Patients treated



Total number of treated persons (2017-2030) 30 221

Patients with achieved SVR




Total number of patients with achieved SVR (2017-2030) 28 645

Basic scenario


WHO scenario

Total number of the infected persons



Reduced number of the infected persons (2017-2030) 89 453

New cases of the infection contamination



Reduction of new infectious diseases (2017-2030) 91 880

Estimated CHC burden – simulation predictions: WHO strategy scenario

Prevalence rate	2017	2030
Chronic hepatitis C (with viremia)	177 980	118 950
Deaths due to liver injury	250	146
Hepatocellular carcinoma	223	135
Decompensated cirrhosis	682	381

Prevented cases	The number of prevented cases as of 2030	The number of prevented newly-diagnosed cases during the period of 2017-2030
Cirrhosis	7 742	51 728
Decompensated cirrhosis	746	5 073
HCC	256	1 750
Death as an outcome of a liver disease	1 875	

Suggestions:

OPTIMIZATION OF THE VIRAL HEPATITIS REGULATORY AND LEGAL FRAMEWORK

- Development and establishment of the National strategy on Viral Hepatitis elimination;

INCREASE IN THE DETECTION FREQUENCY OF VIRAL HEPATITIS

- Implementation of the Federal screening programme on Viral Hepatitis Detection;
- Utilization of modern methods of viral hepatitis laboratory diagnostics in medical establishments throughout all subjects of the Russian Federation

MONITORING OF PATIENTS

- Creation of the integrated registry for the viral hepatitis patients throughout all subjects of the Russian Federation

INCREASE IN ACCESSIBILITY TO TREATMENT

- Increase in accessibility and coverage to modern antiviral treatment for chronic viral hepatitis, due to increase in medical aid to viral hepatitis patients' funding in terms of Compulsory Medical Insurance

ADVANCED PROFESSIONAL TRAINING OF SPECIALISTS

- Upgrading professional level of healthcare personnel, instructing them on modern approaches to diagnostics and treatment of viral hepatitis through information and awareness-raising and educational events (activities)

INCREASE IN POPULATION'S HEALTH AWARENESS

- Executing a set of informative events (popularization/agitation/motivation) with the help of mass media and social organizations.

THANK YOU FOR YOUR ATTENTION!